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To the Editor: We thank the comments by Ng et al.1 on our
report of lamivudine for treating hepatitis B-related mem-
branous nephropathy in subjects with proteinuria exceeding
3 g/day, elevated alanine aminotransferase, and detectable
circulating hepatitis B virus DNA levels.2 We disagree that
only patients who do not remit after 1 year of supportive
therapy should be treated with lamivudine. Although the
spontaneous remission rate was 25% (three out of 12 control
patients), the more important point is that 60% of patients
who received lamivudine went into complete remission by
1 year. Furthermore, of the five subjects who developed end-
stage renal disease in the control group, one (20%) patient
required renal replacement therapy only after 8 months of
disease onset. Indeed, one of the lessons from contemporary
clinical trials is that residual albuminuria at month 6 is a
strong marker of renal outcome.3 The detrimental effect of
albuminuria in intra-renal inflammation and subsequently
fibrosis is also supported by ample experimental data.4 With
such contemporary knowledge and the availability of an
effective yet relatively harmless anti-viral agent, it seems
unethical to delay unremitting subjects for 1 year before
contemplating specific therapy.
Although we agree lamivudine resistance will eventually
emerge with extended usage, we cannot agree that main-
tenance of lamivudine should only last 4–6 months, as
illustrated by the patient who developed disease relapse
shortly after discontinuation of lamivudine that was given for
2 years.
We reiterate that lamivudine improves renal outcome, and
should be considered for patients with documented hepatitis
B-related membranous nephropathy and evidence of liver
disease. Randomized studies with long-term follow-up data
are needed to validate this notion.
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